I believe that in times where the healthcare system is undergoing drastic changes, it is our social responsibility to abdicate for our patients to maintain excellence in care and affordable costs.
Dr. Roberto Ortiz is a graduate of the National University of Colombia, where he earned his medical license in 1989. He moved to Florida in the earlier 90'and began to get involved in Clinical Research that lead to the approval of the first antiretrovirals, he has continued since then participating in HIV and HCV Research. He has managed to mix firsthand experience that he has gained in Research with a robust HIV clinic with a diverse population in terms of gender, age, ethnicity and social groups. Dr Ortiz has participated as a guest speaker for numerous community programs and is an active supporter of the Cheers for Peers program that provides HIV medication adherence education, counseling and peer support to people living with HIV/AIDS in the community. In November 2014 he decided to leave Orlando Immunology Clinic to pursue and other kind of HIV clinic. In May he opens Bliss Healthcare Services a comprehensive clinic for HIV infected and HIV at risk patients offering services like case management, Mental Health, Medications access and Adherence. With extra cost for the patient. Bliss will run very ambitious prevention program, testing, early treatment and PrEP.At Bliss Dr. Ortiz will continue to run the Anal Dysplasia Clinic, where he uses anal pap screening and High Resolution Anoscopy to identify and treat patients with precancerous lesions related to Human Papilloma Virus with a high prevalence in our patients. Dr. Ortiz also offers Sculptra procedures to patients who are suffering from facial fat wasting (lipoatrophy). Transgender population. Dr Ortiz is very active in Research as both as primary investigator clinical trials at bliss the focus with research related to socials issues. He has remained certified as an HIV Specialist through the American Academy of HIV Medicine (AAHIVM) since 01/2001 and serves as a consultant to Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Tibotec and ViiV Pharmaceuticals